Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus MYTELASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus MYTELASE.
ARICEPT ODT vs MYTELASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor